Pyrimidine 2,4-Diones in the Design of New HIV RT Inhibitors.

Chemistry Techniques, Synthetic Drug Design HIV-1 / drug effects Humans Models, Molecular Molecular Structure Protein Binding Pyrimidines / chemical synthesis Quantitative Structure-Activity Relationship Reverse Transcriptase Inhibitors / chemical synthesis
HIV RT inhibitors Pyrimidine-2,4-dione derivatives biological activity molecular docking. reverse nucleosides

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
02 May 2019
Historique:
received: 18 02 2019
revised: 18 03 2019
accepted: 30 04 2019
entrez: 5 5 2019
pubmed: 6 5 2019
medline: 23 8 2019
Statut: epublish

Résumé

The pyrimidine nucleus is a versatile core in the development of antiretroviral agents. On this basis, a series of pyrimidine-2,4-diones linked to an isoxazolidine nucleus have been synthesized and tested as nucleoside analogs, endowed with potential anti-HIV (human immunodeficiency virus) activity. Compounds

Identifiants

DOI: 10.3390/molecules24091718 PMID: 31052607 PMC: PMC6539630
pubmed: 31052607
pii: molecules24091718
doi: 10.3390/molecules24091718
pmc: PMC6539630
pii:
doi:

Substances chimiques

Pyrimidines 0
Reverse Transcriptase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

References

Références

Chem Rev. 2010 Jun 9;110(6):3337-70
pubmed: 20232792
Antiviral Res. 2007 Jul;75(1):52-7
pubmed: 17184854
Curr Pharm Des. 2002;8(8):615-57
pubmed: 11945162
Appl Microbiol Biotechnol. 2018 Dec;102(23):9925-9936
pubmed: 30269214
J Med Chem. 2008 Aug 14;51(15):4641-52
pubmed: 18630898
Expert Opin Pharmacother. 2013 Jun;14(8):1087-96
pubmed: 23560740
Bioorg Med Chem Lett. 2011 Jun 15;21(12):3519-22
pubmed: 21605974
Bioorg Med Chem. 2008 Jan 1;16(1):511-7
pubmed: 17904371
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9412-7
pubmed: 26170311
ChemMedChem. 2009 Feb;4(2):219-24
pubmed: 19090525
Antimicrob Agents Chemother. 2008 Jan;52(1):54-64
pubmed: 17967914
ChemMedChem. 2012 Apr;7(4):565-9
pubmed: 22323191
Expert Opin Pharmacother. 2011 Jan;12(1):31-46
pubmed: 20698725
Angew Chem Int Ed Engl. 2019 Mar 11;58(11):3300-3345
pubmed: 29846032
Curr Opin HIV AIDS. 2014 Jul;9(4):294-301
pubmed: 24824889
J Med Chem. 2011 Jul 14;54(13):4462-73
pubmed: 21568335
Med Res Rev. 2013 Jun;33 Suppl 1:E1-72
pubmed: 21523792
Future Microbiol. 2017 Feb;12:141-155
pubmed: 28106477
J Med Chem. 2011 Apr 28;54(8):3091-6
pubmed: 21438533
J Med Chem. 2005 Mar 24;48(6):2072-9
pubmed: 15771449
Clin Exp Immunol. 2009 Jan;155(1):28-34
pubmed: 19076826
Futur HIV Ther. 2008 Nov 1;2(6):525-537
pubmed: 19881888
Chem Biodivers. 2004 Jan;1(1):44-64
pubmed: 17191775
Antiviral Res. 1998 Jun;38(3):153-79
pubmed: 9754886
Annu Rev Pharmacol Toxicol. 2011;51:1-24
pubmed: 20809796
Antiviral Res. 2010 Jan;85(1):75-90
pubmed: 19781578
N Engl J Med. 2017 Oct 26;377(17):1605-1607
pubmed: 29069566
Curr Med Chem. 2011;18(3):359-76
pubmed: 21143120
J Med Virol. 2016 Jun;88(6):979-86
pubmed: 26519867
Bioorg Med Chem. 2007 Dec 1;15(23):7399-407
pubmed: 17870545
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):225-33
pubmed: 22395670
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10411-6
pubmed: 12915736
Br J Clin Pharmacol. 2010 Dec;70(6):784-93
pubmed: 21175433
PLoS One. 2012;7(11):e48839
pubmed: 23144991
Antiviral Res. 2010 Jan;85(1):34-8
pubmed: 19854224
J Org Chem. 2007 May 11;72(10):3958-60
pubmed: 17419650
Prog Biophys Mol Biol. 2005 Jun;88(2):209-31
pubmed: 15572156
Med Res Rev. 2009 Jul;29(4):611-45
pubmed: 19260077
Bioorg Med Chem. 2012 Jun 1;20(11):3652-7
pubmed: 22549138
Tetrahedron. 2016 Dec 15;72(50):8294-8308
pubmed: 32287430
Med Res Rev. 2008 Nov;28(6):929-53
pubmed: 18438800
J Med Chem. 2016 Apr 14;59(7):2849-78
pubmed: 26509831
Nat Struct Biol. 1995 May;2(5):407-15
pubmed: 7545077
Curr HIV/AIDS Rep. 2010 May;7(2):60-8
pubmed: 20425559
Curr Opin HIV AIDS. 2015 Mar;10(2):116-22
pubmed: 25565175
Eur J Med Chem. 2007 May;42(5):567-79
pubmed: 17223230
J Biol Chem. 2003 Sep 19;278(38):36059-67
pubmed: 12844494
AIDS Res Hum Retroviruses. 2018 Nov;34(11):936-941
pubmed: 29901415
Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1493-504
pubmed: 20929279
Curr Neurol Neurosci Rep. 2016 Jul;16(7):62
pubmed: 27170369
Eur J Med Chem. 2017 Jan 27;126:190-201
pubmed: 27750153
Antiviral Res. 2006 Sep;71(2-3):248-53
pubmed: 16857275
Drug Discov Today. 2011 Aug;16(15-16):715-21
pubmed: 21624501
Bioorg Med Chem. 2013 Sep 15;21(18):5688-93
pubmed: 23932449
J Med Virol. 2014 Jan;86(1):1-7
pubmed: 24068579
AIDS Res Ther. 2016 Apr 27;13:21
pubmed: 27127532
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
HIV Med. 2013 Apr;14(4):195-207
pubmed: 22998068
Expert Opin Ther Pat. 2014 Nov;24(11):1199-227
pubmed: 25313716
Bioorg Med Chem. 2006 Feb 15;14(4):955-9
pubmed: 16213735
Bioorg Med Chem. 2010 Jul 1;18(13):4601-5
pubmed: 20570527
J Med Chem. 2012 Apr 26;55(8):3595-613
pubmed: 22268494

Auteurs

Roberto Romeo (R)

Dipartimento di Scienze chimiche, biologiche, farmaceutiche ed ambientali, Università di Messina, Via S.S. Annunziata, 98168 Messina, Italy. robromeo@unime.it.

Daniela Iannazzo (D)

Dipartimento di Ingegneria, Università di Messina, Contrada Di Dio, 98166 Messina, Italy. diannazzo@unime.it.

Lucia Veltri (L)

Dipartimento di Chimica e tecnologie chimiche, Università della Calabria,Via P. Bucci 12/C, 87036 Arcavacata di Rende, Italy. lucia.veltri@unical.it.

Bartolo Gabriele (B)

Dipartimento di Chimica e tecnologie chimiche, Università della Calabria,Via P. Bucci 12/C, 87036 Arcavacata di Rende, Italy. bartolo.gabriele@unical.it.

Beatrice Macchi (B)

Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma "Tor Vergata", 00133 Roma, Italy. macchi@med.uniroma2.it.

Caterina Frezza (C)

Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma "Tor Vergata", 00133 Roma, Italy. catafrezza@hotmail.it.

Francesca Marino-Merlo (F)

IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy. fmarino@unime.it.

Salvatore V Giofrè (SV)

Dipartimento di Scienze chimiche, biologiche, farmaceutiche ed ambientali, Università di Messina, Via S.S. Annunziata, 98168 Messina, Italy. sgiofre@unime.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Technologie pharmaceutique › Techniques de chimie synthétique › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Conception de médicament › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Relation quantitative structure-activité › Pyrimidine 2,4-Diones in the Design of New HIV...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Inhibiteurs de la transcriptase inverse › Pyrimidine 2,4-Diones in the Design of New HIV...